Regeneron Scores Win in Late-Stage Rheumatoid Arthritis Trial

Regeneron Scores Win in Late-Stage Rheumatoid Arthritis Trial

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 monotherapy study met its primary endpoint demonstrating …

(Visited 3 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.